Literature DB >> 17237154

Identification and functional assessment of BCRP polymorphisms in a Korean population.

Sang Seop Lee1, Hye-Eun Jeong, Joo-Mi Yi, Hyun-Ju Jung, Jae-Eun Jang, Eun-Young Kim, Su-Jun Lee, Jae-Gook Shin.   

Abstract

The breast cancer resistance protein (BCRP) is a member of the ATP-binding cassette transporters. The aim of the present study was to identify genetic variants of BCRP in Koreans and to assess the functional consequences of BCRP polymorphisms. Twenty single nucleotide polymorphisms (SNP), including four nonsynonymous SNP, were identified by DNA sequencing of the BCRP gene in 92 Korean subjects. BCRP V12M, Q141K, P269S, and Q126Stop were detected at frequencies of 23, 28, 0.2, and 1.9%, respectively. These four coding variants were also screened in Chinese and Vietnamese subjects; the allelic frequencies among the three populations were compared; and predictions were made as to the potential frequency of each variant. In vitro functional analyses of the P269S protein and the promoter SNP -19031C>T (mutated in the hypoxia-inducible factor-1alpha binding site) were performed and compared with those of the wild type. P269S exhibited a 35 to 40% decrease in vesicular uptake of [(3)H]estrone-3-sulfate and [(3)H]methotrexate compared with the wild type. The promoter SNP -19031C>T did not affect BCRP promoter activity in either the presence or absence of chemical-induced hypoxic stress. Our results suggest that the P269S variant could be a functionally altered variant. Genotyping of this variant in clinical studies is needed to address its phenotypic role. Genetic polymorphisms of BCRP were found to be very common in Koreans, as well as in other ethnic groups. Comparative analyses among three Asian populations revealed different frequencies for the four functional BCRP variants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237154     DOI: 10.1124/dmd.106.012302

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  ABCG2 null alleles define the Jr(a-) blood group phenotype.

Authors:  Teresa Zelinski; Gail Coghlan; Xiao-Qing Liu; Marion E Reid
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

2.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

3.  Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.

Authors:  Bruce K Birmingham; Sarah R Bujac; Robert Elsby; Connie T Azumaya; Julie Zalikowski; Yusong Chen; Kenneth Kim; Helen J Ambrose
Journal:  Eur J Clin Pharmacol       Date:  2015-01-30       Impact factor: 2.953

4.  Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.

Authors:  Carole Saison; Virginie Helias; Bryan A Ballif; Thierry Peyrard; Hervé Puy; Toru Miyazaki; Sébastien Perrot; Muriel Vayssier-Taussat; Mauro Waldner; Pierre-Yves Le Pennec; Jean-Pierre Cartron; Lionel Arnaud
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

5.  Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats.

Authors:  Wei Yue; Jin Kyung Lee; Koji Abe; Yuichi Sugiyama; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2010-11-24       Impact factor: 3.922

6.  The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

Authors:  Kimberly K Adkison; Soniya S Vaidya; Daniel Y Lee; Seok Hwee Koo; Linghui Li; Amar A Mehta; Annette S Gross; Joseph W Polli; Yu Lou; Edmund J D Lee
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

7.  Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Authors:  R Donald Harvey; Noemi Reguart Aransay; Nicolas Isambert; Jong-Seok Lee; Tobias Arkenau; Johan Vansteenkiste; Paul A Dickinson; Khanh Bui; Doris Weilert; Karen So; Karen Thomas; Karthick Vishwanathan
Journal:  Br J Clin Pharmacol       Date:  2018-10-10       Impact factor: 4.335

8.  Polymorphisms of SLC22A9 (hOAT7) in Korean Females with Osteoporosis.

Authors:  Seong Kyu Ahn; Chang Kook Suh; Seok Ho Cha
Journal:  Korean J Physiol Pharmacol       Date:  2015-06-30       Impact factor: 2.016

9.  Pharmacogenetic study of deferasirox, an iron chelating agent.

Authors:  Ji Won Lee; Hyoung Jin Kang; Ji-Yeob Choi; Nam Hee Kim; Mi Kyung Jang; Chang-Woo Yeo; Sang Seop Lee; Hyery Kim; June Dong Park; Kyung Duk Park; Hee Young Shin; Jae-Gook Shin; Hyo Seop Ahn
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

10.  Computational analysis and predictive modeling of polymorph descriptors.

Authors:  Yugyung Lee; Sourav Jana; Gayathri Acharya; Chi H Lee
Journal:  Chem Cent J       Date:  2013-02-04       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.